AM 9022

Key Product Details

Product Description

AM 9022 is a potent and selective KIF18A inhibitor (IC₅₀ = 60 nM). Displays selectivity for KIF18A over a panel of diverse kinesin motor proteins. Upon blocking MT-ATPase motor activity (non-competitive with ATP and MTs), it activates the mitotic checkpoint and selectively kills chromosomally unstable cancer cells. Has minimal detrimental effects on human bone marrow cells in culture. In mice, AM 9022 leads to tumor regression. AM 9022 can be used for the selective targeting of CIN cancers.

Product Specifications for AM 9022

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for AM 9022

The following data is based on the product molecular weight 578.68.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.73 mL	8.64 mL	17.28 mL
5 mM	0.35 mL	1.73 mL	3.46 mL
10 mM	0.17 mL	0.86 mL	1.73 mL
50 mM	0.03 mL	0.17 mL	0.35 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Payton Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers. Nature Cancer 2023 PMID: 38151625

Product Documents for AM 9022